期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP3A5基因多态性与肿瘤的个体化治疗

Polymorphisms of CYP3A5 Gene and Individualized Treatment for Cancer
下载PDF
导出
摘要 CYP3A5是重要的药物代谢酶,主要的多态性是CYP3A5*3突变,后者使CYP3A5表达和活性降低或消失,文章就CYP3A5*3变异基因对肿瘤发生、治疗、预后的关系作一综述。
作者 沈莉菁 陈芳源
机构地区 上海交通大学医学院附属仁济医院
出处 《肿瘤学杂志》 CAS 2007年第3期243-246,共4页 Journal of Chinese Oncology
关键词 多态性 单核苷酸 肿瘤 基因 CYP3A5 细胞色素P450
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects [J].Br J Clin Pharmacol, 2003, 55(3):264-269,
  • 2Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001,27(4):383-391.
  • 3Wrighton SA,Brian WR,Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450 Ⅲ A5 (HLp3)[J]. Mol Pharmacol, 1990, 38(2):207-213.
  • 4Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism[J]. Mol Pharmacol, 2002,62(1): 162-172.
  • 5Jounaidi Y, Hyrailles V, Gervot L, et al. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?[J]. Biochem Biophys Res Commun, 1996, 221(2):466-470.
  • 6Kim KA, Park PW, Lee OJ, et al.Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects[J]. Clin Pharmacol Ther, 2006, 80(6):646-656.
  • 7Park JY, Kim KA, Park PW, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects[J]. Clin Pharmacol Ther,2006, 79(6):590-599.
  • 8Bochud M, Eap CB, Elston RC, et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families[J]. J Hypertens, 2006, 24(5):923-929.
  • 9Quaranta s, Chevalier D, Bourgarel-Rey V, et al. Identifi cation by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population[J]. Toxicol Lett, 2006, 164(2):177-184.
  • 10Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450m A5(HLP3)[J]. Mol Pharmacol, 1990, 38(2):207-213.

二级参考文献11

  • 1Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286:487-491.
  • 2Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001, 27: 383-391.
  • 3Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5 * 3and * 6, in a Japanese population. Pharmacogenetics, 2002, 12:331-334.
  • 4Hall SD, Thummel KE, Watkins, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos, 1999,27: 161-166.
  • 5Hustert E, Habert M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 2001, 11 :773-779.
  • 6Zhu B, Chen GL, Chen XP, et al. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol Sin, 2002, 23: 567-571.
  • 7Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 2002, 74: 1486-1489.
  • 8Kuehl P;Zhang J;Lin Y.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J],2001(4).
  • 9Lamba JK;Lin YS;Schuetz EG.Genetic contribution to variable human CYP3A-mediated metabolism[J],2002(10).
  • 10De Wildt SN;Kearns GL;Leeder JS.Cytochrome P450 3A: ontogeny and drug disposition[J],1999.

共引文献24

肿瘤学杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部